The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

This publication has 29 references indexed in Scilit:

• A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
  Annals of the Rheumatic Diseases, 2013
• A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
  Annals of the Rheumatic Diseases, 2013
• First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
  Nature Reviews Gastroenterology & Hepatology, 2013
• Biosimilars: what clinicians should know
  Blood, 2012
• Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis
  Advances in Therapy, 2012
• Abatacept for Crohn's Disease and Ulcerative Colitis
  Gastroenterology, 2012
• Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry
  Journal of the European Academy of Dermatology and Venereology, 2012
• Biosimilars of Biological Drug Therapies
  Drugs, 2011
• Cost‐effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient‐level cost data
  Alimentary Pharmacology & Therapeutics, 2009
• Evidence of effectiveness: How much can we extrapolate from existing studies?
  The AAPS Journal, 2005